AR118649A1 - Opciones sintéticas hacia la fabricación de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona - Google Patents

Opciones sintéticas hacia la fabricación de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona

Info

Publication number
AR118649A1
AR118649A1 ARP200101024A ARP200101024A AR118649A1 AR 118649 A1 AR118649 A1 AR 118649A1 AR P200101024 A ARP200101024 A AR P200101024A AR P200101024 A ARP200101024 A AR P200101024A AR 118649 A1 AR118649 A1 AR 118649A1
Authority
AR
Argentina
Prior art keywords
compound
formula
alkyl
produce
chloro
Prior art date
Application number
ARP200101024A
Other languages
English (en)
Spanish (es)
Inventor
Ham Cyril Ben
Sbastien Franois Emmanuel Lemaire
Kostiantyn Chernichenko
Duy Chi Trung Cao
Diego Fernando Domenico Broggini
Simon Albert Wagschal
Bin Zheng
Changxia Yuan
Yi Xiao
Carolyn S Wei
Amarjit Singh
Eric M Simmons
Subha Mukherjee
Sergei Kolotuchin
Yu Fan
Nicolas Cuniere
Original Assignee
Bristol Myers Squibb Co
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Janssen Pharmaceutica Nv filed Critical Bristol Myers Squibb Co
Publication of AR118649A1 publication Critical patent/AR118649A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP200101024A 2019-04-11 2020-04-13 Opciones sintéticas hacia la fabricación de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona AR118649A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962832614P 2019-04-11 2019-04-11

Publications (1)

Publication Number Publication Date
AR118649A1 true AR118649A1 (es) 2021-10-20

Family

ID=70457148

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101024A AR118649A1 (es) 2019-04-11 2020-04-13 Opciones sintéticas hacia la fabricación de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona

Country Status (16)

Country Link
US (2) US12378246B2 (cg-RX-API-DMAC7.html)
EP (2) EP4234555A3 (cg-RX-API-DMAC7.html)
JP (2) JP7631218B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260047658A (cg-RX-API-DMAC7.html)
CN (2) CN114375290B (cg-RX-API-DMAC7.html)
AR (1) AR118649A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020272973B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020368A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132365A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192807A1 (cg-RX-API-DMAC7.html)
ES (1) ES2969253T3 (cg-RX-API-DMAC7.html)
IL (1) IL287102B2 (cg-RX-API-DMAC7.html)
MX (2) MX2025014306A (cg-RX-API-DMAC7.html)
SG (1) SG11202111132WA (cg-RX-API-DMAC7.html)
TW (1) TWI880924B (cg-RX-API-DMAC7.html)
WO (1) WO2020210613A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11788071B2 (en) 2020-04-10 2023-10-17 Codexis, Inc. Engineered transaminase polypeptides
EP4225757A1 (en) * 2020-10-12 2023-08-16 Bristol-Myers Squibb Company A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b] [1,7]diazacyclotetradecin-5(6h)-one

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013033777A2 (pt) * 2011-03-15 2016-09-13 Abbvie Inc moduladores de receptor de hormônio nuclear
JP6505727B2 (ja) 2014-01-31 2019-04-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ヘテロ環式p2’基を有する第xia因子阻害剤としてのマクロ環
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (cg-RX-API-DMAC7.html) * 2014-10-01 2018-10-20
CN105294496A (zh) 2015-09-28 2016-02-03 中山大学 一种西酞普兰中间体的制备方法
CN110062757B (zh) 2017-01-18 2022-03-04 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
CN113677682B (zh) 2019-04-16 2023-05-30 华润生物医药有限公司 作为XIa因子抑制剂的大环衍生物
WO2021013209A1 (zh) 2019-07-23 2021-01-28 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
CA3179679A1 (en) 2020-04-10 2021-10-14 Codexis, Inc. Carboxyesterase polypeptides for kinetic resolution

Also Published As

Publication number Publication date
MX2021012286A (es) 2022-04-06
BR112021020368A2 (pt) 2021-12-07
JP2025084766A (ja) 2025-06-03
US20260092066A1 (en) 2026-04-02
KR20220045105A (ko) 2022-04-12
TW202104188A (zh) 2021-02-01
CA3132365A1 (en) 2020-10-15
JP2022526659A (ja) 2022-05-25
US12378246B2 (en) 2025-08-05
EP3953334A1 (en) 2022-02-16
MX2025014306A (es) 2026-01-07
IL287102B2 (en) 2025-12-01
WO2020210613A1 (en) 2020-10-15
EP4234555A2 (en) 2023-08-30
AU2026201396A1 (en) 2026-03-19
TWI880924B (zh) 2025-04-21
IL287102B1 (en) 2025-08-01
EA202192807A1 (ru) 2022-02-24
CN119775276A (zh) 2025-04-08
US20220144836A1 (en) 2022-05-12
IL287102A (en) 2021-12-01
SG11202111132WA (en) 2021-11-29
CN114375290A (zh) 2022-04-19
AU2020272973A1 (en) 2021-12-02
KR20260047658A (ko) 2026-04-08
KR102929951B1 (ko) 2026-02-24
EP3953334B1 (en) 2023-11-22
CN114375290B (zh) 2024-11-29
EP4234555A3 (en) 2024-01-03
JP7885383B2 (ja) 2026-07-06
JP7631218B2 (ja) 2025-02-18
AU2020272973B2 (en) 2025-11-27
ES2969253T3 (es) 2024-05-17

Similar Documents

Publication Publication Date Title
RU2753548C1 (ru) Способ производства никотина
MY147440A (en) Process for making 3-substituted 2-amino-5-halobenzamides
AR040773A1 (es) Pirazoles utiles como inhibidores de gsk-3
BR0110240A (pt) Composto, processo para a preparação de um composto, processo para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica
MX2009005440A (es) Procedimiento para la produccion de derivados de fenilalanina que tienen estructuras de base de quinazolinodiona e intermediarios para la produccion.
ATE538085T1 (de) Verfahren zur herstellung von 2-amino-5- cyanobenzoesäurederivaten
BR112023025104A2 (pt) Um processo inovador para a preparação de diamidas antranílicas
NZ597638A (en) 5-fluoro-2-oxopyrimidine- 1(2h)-carboxylate derivatives
AR051373A1 (es) Procedimiento para la preparacion de analogos aciclicos de nucleotidos de fosfonatos
BRPI0408160B1 (pt) Processo para o preparo de ésteres do ácido nicotínico substituído e intermediários de enamina para uso nesse processo
AR082881A1 (es) Proceso para preparar un derivado de piperidina, intermediario para sintetizar un medicamento
AR060962A1 (es) Proceso de preparacion de derivados de quinazolina e intermediarios de sintesis
DE60229789D1 (de) Verfahren zur herstellung von phenylethylaminen, insbesondere venlafaxin
AR123762A1 (es) Procedimiento para la fabricación de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona
PH12022550985A1 (en) 3-n-cyclopropylmethyl-2-fluorobenzamide compound, preparation method therefor and use thereof
NZ599006A (en) Fluoro-substituted 3,5-dicyano-4-(1h-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof
Hachiya et al. Synthesis of nitrogen-containing heterocycles using conjugate addition reactions of nucleophiles to α, β-unsaturated imines
UA93860C2 (ru) Способ получения пиразолов, способ региоселективного алкилирования и применение фосфата или фосфоната b способе
DE602007002486D1 (de) Verfahren zur herstellung von 1-halogen-2,7-naphthyridinylderivaten
ATE498617T1 (de) Verfahren zur herstellung einer 3-o- alkylascorbinsäure
MX2012008152A (es) Proceso para preparar voriconazol utilizando nuevos intermediarios.
MXPA05003695A (es) Nuevo proceso para la sintesis de compuestos de 1,3-dihidro-2h-3-benzazepin-2-ona, y aplicacion en la sintesis de ivabradina y sales de adicion de la misma con un acido farmaceuticamente aceptable.
EA200501135A1 (ru) Способы получения алкалоидов хиназолина
TW200637856A (en) Process for producing thiazolidinedion compound and intermediate thereof
AU2001228487A1 (en) Utilization of an extracting agent as antifoaming agent in the production of anhydrous formic acid